智通财经APP获悉，再鼎医药(09688)涨超4%，截至发稿，涨4.06%，报20.25港元，成交额2539.39万港元。
消息面上，近日，再鼎医药合作伙伴Novocure(NVCR.US)宣布，美国食品药品监督管理局(FDA)已批准Optune Lua与PD-1/PD-L1抑制剂或多西他赛同时使用，用于治疗转移性非小细胞肺癌(mNSCLC)的成人患者，这些患者在接受含铂的治疗方案期间或之后出现了疾病进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.